HK1140217A1 - The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases - Google Patents

The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases

Info

Publication number
HK1140217A1
HK1140217A1 HK10106855.9A HK10106855A HK1140217A1 HK 1140217 A1 HK1140217 A1 HK 1140217A1 HK 10106855 A HK10106855 A HK 10106855A HK 1140217 A1 HK1140217 A1 HK 1140217A1
Authority
HK
Hong Kong
Prior art keywords
neovasculature
fibrinogen
antigen
tumour metastases
metastases
Prior art date
Application number
HK10106855.9A
Other languages
English (en)
Inventor
Dario Neri
Jascha Rybak
Christoph Roesli
Alessandra Villa
Giovanni Neri
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Publication of HK1140217A1 publication Critical patent/HK1140217A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
HK10106855.9A 2007-04-02 2010-07-14 The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases HK1140217A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90958007P 2007-04-02 2007-04-02
US94856407P 2007-07-09 2007-07-09
PCT/IB2008/000965 WO2008120101A2 (en) 2007-04-02 2008-03-31 The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases

Publications (1)

Publication Number Publication Date
HK1140217A1 true HK1140217A1 (en) 2010-10-08

Family

ID=39791007

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13112184.6A HK1184794A1 (zh) 2007-04-02 2010-07-14 與腫瘤轉移的新生血管有關的纖連蛋白的 抗原
HK10106855.9A HK1140217A1 (en) 2007-04-02 2010-07-14 The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13112184.6A HK1184794A1 (zh) 2007-04-02 2010-07-14 與腫瘤轉移的新生血管有關的纖連蛋白的 抗原

Country Status (13)

Country Link
US (5) US8263041B2 (xx)
EP (2) EP2142567B1 (xx)
JP (2) JP5221641B2 (xx)
KR (1) KR101515243B1 (xx)
CN (2) CN101687923B (xx)
AU (1) AU2008234615B2 (xx)
BR (1) BRPI0809989B8 (xx)
CA (1) CA2682851C (xx)
EA (2) EA018985B1 (xx)
ES (2) ES2609813T3 (xx)
HK (2) HK1184794A1 (xx)
MX (1) MX2009010639A (xx)
WO (1) WO2008120101A2 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0809989B8 (pt) 2007-04-02 2021-05-25 Philogen Spa usos de um anticorpo ou fragmento de ligação a antígeno do mesmo que se liga a isoforma extradomínio-a (ed-a) de fibronectina e/ou ao ed-a de fibronectina
ES2534726T3 (es) * 2007-07-25 2015-04-27 Philogen S.P.A. Antígeno ED-A del fibrinógeno que está asociado con linfomas
US10202442B2 (en) * 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
KR102002739B1 (ko) 2007-10-30 2019-07-23 필로겐 에스.피.에이. 류마티스 관절염과 연관된 항원
EP2379116B1 (en) 2009-01-07 2015-08-26 Philogen S.p.A. Antigens associated with endometriosis
US20110318302A1 (en) 2009-01-07 2011-12-29 Kathrin Schwager Cancer Treatment
ES2640981T3 (es) 2009-08-05 2017-11-07 Philogen S.P.A. Selección como diana de neovasculatura de médula ósea
WO2011156639A1 (en) * 2010-06-10 2011-12-15 The Regents Of The University Of California Eiiia and eiiib segments of fibronectin regulate stem cell fate
JP5548872B2 (ja) * 2010-08-26 2014-07-16 株式会社島津製作所 大腸がん肝転移マーカー、及び試料中の大腸がん肝転移マーカーの分析方法
EP2621535A1 (en) 2010-09-29 2013-08-07 Philogen S.p.A. Thiazolidine linker for the conjugation of drugs to antibodies
EP3437662B1 (en) 2011-07-27 2021-02-17 Philogen S.p.A. Il-12 immunoconjugate
HUE044927T2 (hu) * 2012-10-03 2019-11-28 Philogen Spa Ellenanyag-konjugátum, gyulladásos bélbetegség kezelésében történõ alkalmazásra
AU2014360946B2 (en) 2013-12-12 2020-06-25 Umc Utrecht Holding B.V. Immunoglobulin-like molecules directed against fibronectin-EDA
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
BR112018000909A2 (pt) 2015-07-16 2018-09-11 Philogen Spa imunoconjugados de il22
SG11201903400WA (en) 2016-10-17 2019-05-30 Pfizer Anti-edb antibodies and antibody-drug conjugates
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
AU2018281871B2 (en) 2017-06-07 2022-07-28 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
CN114206355A (zh) * 2019-06-03 2022-03-18 芝加哥大学 用靶向癌症的佐剂治疗癌症的方法和组合物
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
MX2022001799A (es) 2019-08-15 2022-03-11 Janssen Biotech Inc Materiales y metodos para fragmentos variables de cadena unica mejorados.
WO2022018126A1 (en) 2020-07-22 2022-01-27 Philogen S.P.A. Treatment of pulmonary hypertension
CN114350518B (zh) * 2022-01-19 2023-01-13 广东乾晖生物科技有限公司 仿生肝微流控细胞培养-药物筛选芯片
WO2023175077A1 (en) 2022-03-17 2023-09-21 Philogen S.P.A Anti-ed-a antibodies for the treatment of pulmonary hypertension

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
FI892197A (fi) * 1989-05-08 1990-11-09 Locus Oy Foerfarande foer detektering av tumoerer.
US5420012A (en) 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992017604A1 (en) * 1991-03-26 1992-10-15 Otsuka Pharmaceutical Factory, Inc. Anti-eda monoclonal antibody
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
WO2000034784A1 (en) 1998-12-10 2000-06-15 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
DK1719528T3 (da) 2000-02-24 2012-01-09 Philogen Spa Sammensætninger og fremgangsmåder til behandling af angiogenese i patologiske læsioner
CA2404919A1 (en) 2000-04-06 2002-10-01 Kyowa Hakko Kogyo Co. Ltd. Diagnostic and therapeutic agents for rheumatoid arthritis
AU5867901A (en) 2000-05-04 2001-11-12 Philogen S.R.L. Method for detecting tumors
PL364358A1 (en) 2000-09-07 2004-12-13 Schering Ag Receptor in the edb fibronectin domain (ii)
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
CA2468081A1 (en) * 2002-01-03 2003-07-10 Schering Aktiengesellschaft Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
WO2004000216A2 (en) 2002-06-21 2003-12-31 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US7560095B2 (en) 2003-04-22 2009-07-14 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
WO2005086612A2 (en) 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
US7943294B2 (en) * 2004-07-30 2011-05-17 Hologic, Inc. Methods for detecting oncofetal fibronectin
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
CA2586661A1 (en) 2004-11-09 2006-05-18 Philogen S.P.A. Antibodies against tenascin-c
DE602006012667D1 (de) 2005-05-11 2010-04-15 Philogen Spa Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
BRPI0709787A2 (pt) 2006-05-08 2011-03-29 Philogen Spa citocinas com anticorpos alvejados para terapia
BRPI0809989B8 (pt) * 2007-04-02 2021-05-25 Philogen Spa usos de um anticorpo ou fragmento de ligação a antígeno do mesmo que se liga a isoforma extradomínio-a (ed-a) de fibronectina e/ou ao ed-a de fibronectina
ES2534726T3 (es) * 2007-07-25 2015-04-27 Philogen S.P.A. Antígeno ED-A del fibrinógeno que está asociado con linfomas
KR102002739B1 (ko) * 2007-10-30 2019-07-23 필로겐 에스.피.에이. 류마티스 관절염과 연관된 항원
EP2379116B1 (en) * 2009-01-07 2015-08-26 Philogen S.p.A. Antigens associated with endometriosis
EP2621535A1 (en) * 2010-09-29 2013-08-07 Philogen S.p.A. Thiazolidine linker for the conjugation of drugs to antibodies
EP3437662B1 (en) * 2011-07-27 2021-02-17 Philogen S.p.A. Il-12 immunoconjugate
EP2988784A1 (en) * 2013-04-25 2016-03-02 Philogen S.p.A. Antibody-drug conjugates
US20160200789A1 (en) * 2013-04-26 2016-07-14 Philogen S.P.A. Il4 conjugated to antibodies against extracellular matrix components
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
MX2009010639A (es) 2009-10-23
EA201301224A1 (ru) 2014-07-30
AU2008234615B2 (en) 2013-10-10
AU2008234615A1 (en) 2008-10-09
ES2609813T3 (es) 2017-04-24
JP5840631B2 (ja) 2016-01-06
JP2010523541A (ja) 2010-07-15
JP2013121353A (ja) 2013-06-20
BRPI0809989B8 (pt) 2021-05-25
US9181347B2 (en) 2015-11-10
CN103275220A (zh) 2013-09-04
CA2682851A1 (en) 2008-10-09
US20160083461A1 (en) 2016-03-24
BRPI0809989B1 (pt) 2019-10-08
KR101515243B1 (ko) 2015-04-24
CN101687923B (zh) 2013-06-19
US9896503B2 (en) 2018-02-20
EA200970909A1 (ru) 2010-10-29
CN103275220B (zh) 2016-01-20
EA018985B1 (ru) 2013-12-30
KR20100016094A (ko) 2010-02-12
WO2008120101A2 (en) 2008-10-09
US8481684B2 (en) 2013-07-09
US20130040361A1 (en) 2013-02-14
US20100247541A1 (en) 2010-09-30
US20130280759A1 (en) 2013-10-24
US8263041B2 (en) 2012-09-11
JP5221641B2 (ja) 2013-06-26
CA2682851C (en) 2017-01-17
HK1184794A1 (zh) 2014-01-30
EP2653478B1 (en) 2016-10-05
ES2402171T3 (es) 2013-04-29
CN101687923A (zh) 2010-03-31
EP2142567A2 (en) 2010-01-13
EP2653478A1 (en) 2013-10-23
EP2142567B1 (en) 2013-01-16
WO2008120101A3 (en) 2008-12-11
EA036322B1 (ru) 2020-10-26
US20130266511A1 (en) 2013-10-10
BRPI0809989A2 (pt) 2015-09-29

Similar Documents

Publication Publication Date Title
HK1140217A1 (en) The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases
WO2009013619A3 (en) The ed-a antigen of fibrinogen is associated with the neovas culature of tumor metastases
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
MX2010004726A (es) Antigeno asociado con artritis reumatoide.
CY1119218T1 (el) Αναστολεις διυδροπυριδοφθαλαζινονης της πολυμερασης της πολυαδενοσφωσφορικης ριβοζης (parp)
SG159458A1 (en) Novel immunoglobulin-binding proteins with improved specificity
CY1112102T1 (el) Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
UA100874C2 (xx) Двовалентні біспецифічні антитіла$двухвалентные биспецифические антитела
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
MA32938B1 (fr) Composes organiques
UA113397C2 (xx) Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3
MX2012003396A (es) Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
CY1112595T1 (el) Αμιδοφαινοξυινδαζολια χρησιμα ως αναστολεις του c-met
IN2014DN10428A (xx)
MY151047A (en) Iron (iii)-carbohydrate based phosphate adsorbent
WO2010078945A3 (en) Cancer treatment
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
MX2011013351A (es) Materiales de soporte inorgánicos que contienen compuestos de 3 anillos heterocíclicos.
TW200728310A (en) Process for the preparation of ferri-succinylcasein
MX2009013069A (es) Tratamiento de leucemia resistente al imatinib.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230404